CHILDREN'S HOSPITAL CORPORATION

Their core work

Boston Children's Hospital is one of the largest pediatric medical centers in the United States, combining clinical care with biomedical research across a wide range of childhood and adult diseases. In H2020, they contributed specialist clinical and research expertise in pain medicine, pediatric neurology, immunology, and regenerative medicine. Their role has consistently been as a US-based third-party or partner bringing deep translational research capabilities to European consortia, particularly in areas where their clinical datasets and patient access add unique value.

What they specialise in

How they've shifted over time

Their early H2020 work (2015–2018) centered on child health systems, inflammatory bowel disease, and the beginnings of pain research. From 2018 onward, the focus shifted markedly toward neuroscience (pediatric epilepsy detection), regenerative medicine (cartilage repair, steroid-producing organoids, diabetes cell therapies), and advanced immunology. This trajectory suggests a move from population-level health services research toward more mechanistic, translational biomedical science.

They are increasingly engaged in translational biomedical research — particularly neuroimaging, tissue engineering, and immunoengineering — suggesting future collaborations should target these mechanistic and therapeutic areas.

How they like to work

CHB has never coordinated an H2020 project; they join as a participant or, more commonly, as a third-party contributor (6 of 9 projects). This reflects their position as a US-based institution that European consortia bring in for specialized clinical or research capabilities rather than administrative leadership. With 76 unique partners across 22 countries, they connect to a broad and diverse network, indicating they are a sought-after specialist rather than a repeat partner within a tight cluster.

They have collaborated with 76 unique partners across 22 countries, giving them an exceptionally wide network for an organization with only 9 projects. This breadth reflects their role as a US specialist invited into diverse European consortia rather than building a fixed partner base.

What sets them apart

As a major US pediatric research hospital participating in European Framework Programme projects, CHB offers something few European partners can: access to large American patient cohorts, specialized pediatric clinical infrastructure, and deep expertise at the intersection of childhood disease and translational research. Their willingness to join as a third party makes them an accessible partner — they bring high-value clinical and research input without competing for coordination roles. For consortium builders, they represent a credible transatlantic bridge, particularly in pediatric neurology, pain medicine, and immunology.

Highlights from their portfolio

• IMI-PainCare
  Their largest funded project (EUR 165,668), addressing a major clinical challenge in pain management with a sophisticated approach combining biomarkers, patient stratification, and PROMs.
• HOPE
  Focused on automatic detection of high-frequency oscillations in pediatric epilepsy — a highly specialized niche combining neuroimaging technology with pediatric clinical expertise.
• LeukoTheranostics
  Their highest single funding (EUR 175,517), combining nanotechnology with immunology to reprogram leukocytes in inflammatory bowel disease — a strong example of translational research.